NCT05222217

Brief Summary

Faecal incontinence has a broad spectrum of symptoms. Some patients only suffer commonly considered mild symptoms: gas incontinence and soiling, but patients' quality of life is significantly impaired. Although several treatments for faecal incontinence are available, this subgroup of patients are difficult to treat, and no therapeutic alternative has been clearly defined. The aim of this study is to evaluate Gatekeeper™ treatment for this subgroup of patients with faecal incontinence, not studied before. Consecutive case series single-centre study. Patients with mainly soiling and/or gas incontinence were treated with polyacrylonitrile prostheses

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
13

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2014

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2015

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
6.1 years until next milestone

First Submitted

Initial submission to the registry

December 24, 2021

Completed
1 month until next milestone

First Posted

Study publicly available on registry

February 3, 2022

Completed
Last Updated

February 3, 2022

Status Verified

February 1, 2022

Enrollment Period

1.8 years

First QC Date

December 24, 2021

Last Update Submit

February 2, 2022

Conditions

Outcome Measures

Primary Outcomes (3)

  • Change in the number of gas incontinence and soiling episodes

    Each patient completes a three-week continence diary specifically recording gas incontinence and soiling episodes at baseline and before every follow-up visit.

    6, 12 and 24 months after surgery

  • Changes in incontinence symptoms

    Evaluation of incontinence symptoms with the St. Mark's Incontinence Score. Score from 0 to 24, where 0 means "complete continence" and 24 means "severe fecal incontinence"

    6, 12 and 24 months after surgery

  • Patient's Subjective Perception

    Changes in patient subjective evaluation using a Visual Analogue Scale (VAS). Score from 0 to 10, where 0 means "no problem" and 10 means "severe problem and alteration of my quality of life"

    6, 12 and 24 months after surgery

Secondary Outcomes (2)

  • Changes in prostheses location

    baseline and one month after surgery

  • Differences in anal pressures

    baseline and three months after surgery

Interventions

Six polyacrylonitrile prostheses (THD Gatekeeper™ Delivery System, THD SpA, Correggio, Italy) were implanted under 3D-EUS control through a 5mm perianal incision at 1, 3, 5, 7, 9 and 11 o'clock in lithotomy position, and located in the upper-middle intersphincteric space of the anal canal, using a specifically designed system.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients' selection was based on clinical history, physical examination, preoperative 3D-endoanal ultrasound (EUS) and a continence diary recorded for 21 days. Patients with previous history of chronic diarrhoea were evaluated by the gastroenterology team and if needed, fibre supplementation or other medical treatment was used to obtain a Bristol score of 3-4 before entering the study

You may qualify if:

  • patients older than 18 years old
  • with at least 6 months of GI and/or soiling
  • non-responding to conservative treatment and biofeedback.

You may not qualify if:

  • complete solid and liquid FI
  • common Bristol score \> 4
  • malignant diseases
  • chronic diarrhoea
  • inflammatory bowel disease
  • acute anorectal disease
  • rectal prolapse
  • neurological disease,
  • obstructive defecation syndrome
  • low anterior resection syndrome,
  • previous pelvic radiation,
  • any anaesthetic contraindication
  • St. Mark's score \> 12
  • external anal sphincter lesion \> 30º.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Fecal Incontinence

Condition Hierarchy (Ancestors)

Rectal DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Chief of General and Digestive Surgery

Study Record Dates

First Submitted

December 24, 2021

First Posted

February 3, 2022

Study Start

January 1, 2014

Primary Completion

November 1, 2015

Study Completion

December 1, 2015

Last Updated

February 3, 2022

Record last verified: 2022-02

Data Sharing

IPD Sharing
Will not share